Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980710/0/en/Sutro-Biopharma-Reports-Third-Quarter-2024-Financial-Results-and-Business-Highlights.html
04 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/04/2974424/0/en/Sutro-Biopharma-Demonstrates-Meaningful-ADC-Innovation-with-Five-Presentations-at-the-15th-Annual-World-ADC-Conference.html
01 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/01/2973317/0/en/Sutro-Biopharma-Announces-Initiation-of-the-Registration-enabling-REFR%CE%B1ME-P1-Trial-with-Luvelta-for-Pediatric-Patients-with-CBF-GLIS-AML.html
10 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/10/2961683/0/en/Sutro-Biopharma-Highlights-Next-Generation-ADC-Innovation-and-Near-term-Pipeline-at-Research-Forum.html
20 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/20/2949878/0/en/Sutro-Biopharma-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
14 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/14/2946228/0/en/Sutro-Biopharma-Announces-Updated-Data-from-Phase-1b-Study-of-Luvelta-in-Combination-with-Bevacizumab-at-ESMO-2024.html
Details:
Luvelta (luveltamab tazevibulin) is an FOLR1 antagonist antibody-drug conjugate, which is being evaluated for the treatment of patients with non-small cell lung cancer.
Lead Product(s): Luveltamab Tazevibulin
Therapeutic Area: Oncology Brand Name: Luvelta
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2024
Sutro Biopharma Starts Phase 2 Trial of Luvelta for Lung Cancer
Details : Luvelta (luveltamab tazevibulin) is an FOLR1 antagonist antibody-drug conjugate, which is being evaluated for the treatment of patients with non-small cell lung cancer.
Brand Name : Luvelta
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 22, 2024
Details:
The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.
Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology Brand Name: Luvelta
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: VGXI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 03, 2024
Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : VGXI
Deal Size : Undisclosed
Deal Type : Partnership
VGXI, Sutro Partner to Support Sutro's Clinical Pipeline
Details : The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.
Brand Name : Luvelta
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 03, 2024
Details:
STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated for ovarian cancers in combination with Pegfilgrastim.
Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology Brand Name: Luvelta
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Details : STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated for ovarian cancers in combination with Pegfilgrastim.
Brand Name : Luvelta
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for FOLR1-expressed Ovarian Neoplasms.
Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology Brand Name: STRO-002
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: BofA Securities
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 02, 2024
Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BofA Securities
Deal Size : $75.0 million
Deal Type : Public Offering
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Details : Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for FOLR1-expressed Ovarian Neoplasms.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 02, 2024
Details:
Under the licensing agreement, Ipsen has exclusive worldwide rights to develop and commercialize STRO-003, an ROR1 inhibitor currently undergoing clinical evaluation for the treatment of neoplasms.
Lead Product(s): STRO-003
Therapeutic Area: Oncology Brand Name: STRO-003
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 02, 2024
Lead Product(s) : STRO-003
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Ipsen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ipsen and Sutro Announce Global Licensing Agreement For ADC Targeting Solid Tumors
Details : Under the licensing agreement, Ipsen has exclusive worldwide rights to develop and commercialize STRO-003, an ROR1 inhibitor currently undergoing clinical evaluation for the treatment of neoplasms.
Brand Name : STRO-003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 02, 2024
Details:
Under the agreement, Vaxcyte obtains exclusive rights to independently develop and manufacture cell-free extract, a key component of the company’s 24-valent pneumococcal conjugate vaccine (PCV) franchise which includes VAX-24 and VAX-31.
Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: VAX-24
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Vaxcyte
Deal Size: $135.0 million Upfront Cash: $135.0 million
Deal Type: Agreement November 27, 2023
Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vaxcyte
Deal Size : $135.0 million
Deal Type : Agreement
Details : Under the agreement, Vaxcyte obtains exclusive rights to independently develop and manufacture cell-free extract, a key component of the company’s 24-valent pneumococcal conjugate vaccine (PCV) franchise which includes VAX-24 and VAX-31.
Brand Name : VAX-24
Molecule Type : Vaccine
Upfront Cash : $135.0 million
November 27, 2023
Details:
The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine.
Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: VAX-24
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Blackstone Life Sciences
Deal Size: $390.0 million Upfront Cash: $140.0 million
Deal Type: Collaboration June 26, 2023
Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Blackstone Life Sciences
Deal Size : $390.0 million
Deal Type : Collaboration
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
Details : The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate v...
Brand Name : VAX-24
Molecule Type : Vaccine
Upfront Cash : $140.0 million
June 26, 2023
Details:
STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated in a phase 1 clinical trial for ovarian and endometrial cancers. FDA has also granted the fast track designation for STRO-002.
Lead Product(s): Luveltamab Tazevibulin
Therapeutic Area: Oncology Brand Name: STRO-002
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details : STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated in a phase 1 clinical trial for ovarian and endometrial cancers. FDA has also granted the fast track designation for STRO-002.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 09, 2023
Details:
Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.
Lead Product(s): STRO-002,Bevacizumab
Therapeutic Area: Oncology Brand Name: STRO-002
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Lead Product(s) : STRO-002,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 21, 2022
Details:
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease.
Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: VAX-24
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Vaxcyte
Deal Size: $157.5 million Upfront Cash: $157.5 million
Deal Type: Agreement December 20, 2022
Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vaxcyte
Deal Size : $157.5 million
Deal Type : Agreement
Details : Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease.
Brand Name : VAX-24
Molecule Type : Vaccine
Upfront Cash : $157.5 million
December 20, 2022
ABOUT THIS PAGE
Sutro Biopharma is a supplier offers 6 products (APIs, Excipients or Intermediates).
Find a price of Aminoacyl tRNA synthetase-IN-1 bulk with DMF offered by Sutro Biopharma
Find a price of polymerases bulk with DMF offered by Sutro Biopharma
Find a price of SP6188 PREFABRICATED LIGHT CHAIN (PFLC) bulk with DMF offered by Sutro Biopharma
Find a price of XTRACTCF™ REAGENT bulk with DMF offered by Sutro Biopharma
Find a price of SC239 DRUG-LINKER bulk with DMF offered by Sutro Biopharma
Find a price of PEPTIDE DEFORMYLASE REAGENT bulk with DMF offered by Sutro Biopharma
LOOKING FOR A SUPPLIER?